Nara Medical University
12
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
8.3%
1 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
33%
4 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)
Role: collaborator
AI-Powered Scoliosis Auto-Analysis System Multicenter Development and Validations
Role: collaborator
Flow Patterns and Stent Thrombosis
Role: collaborator
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Role: collaborator
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
Role: collaborator
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
Role: collaborator
Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy
Role: collaborator
Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
Role: lead
Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline
Role: lead
New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering
Role: lead
The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure
Role: lead
Hemofiltration for Contrast-Induced Nephropathy
Role: lead
All 12 trials loaded